IMMUNOTEC INC. VAUDREUIL-DORION, QC, April 8, 2016 - Immunotec Inc. (TSXV: IMM), a direct-to-consumer company and a leader in the nutritional industry (the "Company" or "Immunotec"), is pleased to announce the renewal, for a five (5) year period, of its Supply and Manufacturing Agreement with Glanbia Nutritionals ("Glanbia"). This new contract replaces the previous agreement signed in May 2011.
"Glanbia has been a strategic partner and the exclusive distributor of a proprietary Whey Protein Isolate used in our formulation of Immunocal® and Immunocal Platinum® products since the commercial beginnings of the Company, 20 years ago" said Charles L. Orr, Chief Executive Officer of Immunotec. "We value our relationship with Glanbia which goes beyond the supply of product and constitutes a true collaboration."
Glanbia Nutritionals is a division of Glanbia plc, a global nutrition group headquartered in Kilkenny, Ireland. Glanbia takes pure and clean ingredients including milk, whey and grains, and using their expert knowledge and capabilities produces high-quality nutritional ingredients and branded consumer products for customers and consumers worldwide. The Group has over 6,000 employees across 32 countries with products sold or distributed in over 130 countries. The Group has operations in Ireland, the UK, Germany, USA, and China, as well as strategic international joint ventures and associates in the UK, Ireland and USA. Glanbia is listed on both the Dublin and London Stock Exchange. Glanbia is the No. 1 global producer of whey based nutritional solutions, the No. 1 global producer of American style cheese, and the No. 2 global provider of custom blended micronutrient premixes. Glanbia Nutritionals is on the forefront in the exploration of science and the dynamics that drive the growing nutrition industry. For more information visit www.glanbianutritionals.com or contact Eric Borchardt, Director of Marketing, Glanbia Nutritionals.
Immunotec is a Canadian-based company that develops, manufactures, markets and sells research-driven nutritional products through direct-to-consumer sales channels in Canada, the U.S., Mexico, the Dominican Republic, the United Kingdom and Ireland. The company offers an extensive line of nutritional, skin care and wellness products targeting health, weight management, energy and physical performance. Please visit us at www.immunotec.com for additional information.
The company files its continuous disclosure documents, inclusive of its year end results, on the SEDAR database at www.sedar.com and on the Company's website at www.immunotec.com. The common shares of the Company are listed on the TSX Venture Exchange under the ticker symbol IMM. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Immunotec Inc. issued this content on 08 April 2016 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 11 April 2016 14:26:30 UTC
Original Document: http://www.immunotec.com/IRL/Public/en/pdfs/PressRelease_16-04-08_GlanbiaContract.pdf
